Year in Review
CSL Pharmaceutical Products
Annual Report Contents > Business Features > CSL Pharmaceutical Feature > CSL Pharmaceutical Products
banner


Major pharmaceutical products marketed by CSL
 

Vaccines
 

For prevention of:

Fluvax®
Pneumovax* 23
Menjugate*
ADT®
Tet-Tox®
H-B-Vax* II
PedvaxHIB*
Vaqta*
Varivax* Refrigerated
Comvax*
Q-Vax®
MMR*II
Influenza
Pneumococcal infection
Meningococcal C disease
Diphtheria and Tetanus
Tetanus
Hepatitis B infection
Haemophilus influenzae B
Hepatitis A infection
Varicella
Haemophilus influenzae B and Hepatitis B infection
Q-Fever
Measles, mumps and rubella


Anti-infectives For treatment of:
 

Flopen®
Moxacin®
Fucidin*
BenPen®
Severe staphylococcal infections
Bacterial infections
Bacterial infections
Bacterial infections

Other products

For treatment of:
 

Tramal*
Flomax*
Antivenoms
Cervidil*
Modavigil*
Epi-Pen*
Daivobet*
Daivonex*
Moderate to severe pain
Benign prostatic hyperplasia
Envenomation
Complications during childbirth requiring induced labour
Excessive daytime sleepiness in narcolepsy
Severe allergic reactions
Psoriasis
Psoriasis


Trademarks
 

CSL, Bioplasma and ZLB are all trademarks of the CSL Group.
® Registered trademark of CSL Limited or its affiliates.
Trademark of CSL Limited or its affiliates.
* Trademarks of companies other than CSL and referred to in this Annual Report are listed below:

     Controlled Therapeutics (Scotland) Limited Cervidil
 
     Leo Pharmaceutical Products Limited AS

Daivonex
Daivobet
Fucidin
 

     Merck & Co. Inc.

Comvax
H-B-Vax II
M-M-R II
PedvaxHIB
Pneumovax
Vaqta
Varivax 
 

     Yamanouchi Europe BV Flomax
 
     Grunenthal GmbH Tramal
 
     Chiron SpA Menjugate
 
     Genelco SA Modavigil
 
     Merck KGaA EpiPen

 


Back | Next